China Diagnostic Reagent Industry Report, 2010
  • Oct/2010
  • Hard Copy
  • USD $1,100
  • Pages:43
  • Single User License
    (PDF Unprintable)       
  • USD $1,200
  • Code: YF007
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,300
In 2009, China’s diagnostic reagent market represented about 5% of the global market, and Chinese enterprises still concentrated on low-end biochemistry diagnostic reagent market.

In China, there had been more than 70 biochemistry diagnostic reagent producers by the end of 2009, with sales over RMB 4 billion in total. At present, there are only about a dozen of immune diagnostic reagent producers with sales of RMB 1.5 billion in total, and there are no more than five nucleic acid diagnostic reagent producers with the market size of no more than RMB 500 million in all. By contrast, in foreign markets, the share of biochemistry diagnostic reagent has become very low, while immune diagnostic reagent and nucleic acid diagnostic reagent featuring higher detection sensitivity and specificity have become the mainstream.

The major diagnostic reagent producers in China include KHB and Da An Gene, all of which hold certain market shares by virtue of their own technology strength. Da An Gene mainly produces nucleic acid diagnostic reagent which can compete with the international advanced level in technology and quality. In 2009, Da An Gene’s nucleic acid diagnostic reagent business accounted for over 50% of the company’s operating income and about 60% of the domestic nucleic acid diagnostic reagent market. In addition, with the launch of China nucleic acid blood screening market, the nucleic acid blood screening business is expected to become a new profit point of Da An Gene.

Operating Income and YoY Growth of Nucleic Acid Diagnostic Reagent Sector of Da An Gene, 2006-2009
Source: Announcement of Da An Gene; ResearchInChina
1. Industry Profile 
1.1 Definition and Classification
1.2 Industrial Chain
1.2.1Upstream Market 
1.2.2 Downstream Market 

2. Operating Environment in China
2.1 Global Market 
2.1.1 Development of Biopharmaceutical Industry Worldwide
2.1.2 Development of Diagnostic Reagent Industry Worldwide
2.2 Chinese Market
2.2.1 Development of Biopharmaceutical Industry in China
2.2.2 Relevant Policies of China

3. Development in China
3.1 Overview 
3.2 Import & Export
3.3 Market Segments
3.3.1 Biochemistry Diagnostic Reagent 
3.3.2 Immune Diagnostic Reagent 
3.3.3 Nucleic Acid Diagnostic Reagent 
3.4 Development Tendency of Diagnostic Reagent Sector in China

4. Domestic Major Producers
4.1 KHB
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Operation of Diagnostic Reagent Business
4.2 Da An Gene
4.2.1 Profile
4.2.2 Operation
4.2.3 Operation of Diagnostic Reagent Business
4.3 Fosun Pharmaceutical (Group)
4.3.1 Profile
4.3.2 Operation
4.4 Biosino Bio-Technology & Science Inc 
4.4.1 Profile
4.4.2 Operation
4.5 Zhuhai Livzon Diagnostics
4.5.1 Profile
4.5.2 Operation
4.6 ACON Laboratories
4.6.1 Profile
4.6.2 Operation
4.7 Beijing Wantai Biological Pharmacy
4.7.1 Profile
4.7.2 Operation
4.8 Shanghai Rongsheng Biotech
4.8.1 Profile
4.8.2 Operation
4.9 Beijing Chemclin Biotech
4.9.1 Profile
4.9.2 Operation
4.10 PG Biotech
4.10.1 Profile
4.10.2 Major Products
4.11 Kinghawk Pharmaceutical 
4.11.1 Profile
4.11.2 Operation
4.12 ABON Biopharm (Hangzhou)
4.12.1 Profile
4.12.2 Operation
4.13 Shanghai Upper Bio-Tech Pharma
4.13.1 Profile
4.13.2 Operation
4.14 Beijing Leadman Biochemical
4.14.1 Profile
4.14.2 Operation
4.15 Blue Cross Bio-Medical (Beijing)
4.15.1 Profile
4.15.2 Operation
4.16 Inverness Medical (Shanghai)
4.16.1 Profile
4.16.2 Operation
4.17 Baso Diagnostics
4.17.1 Profile
4.17.2 Operation
4.18 Beijing North Institute of Biological Technology
4.18.1 Profile
4.18.2 Operation
4.19 DiaSys Diagnostic Systems (Shanghai)
4.19.1 Profile
4.19.2 Operation
4.20 Other Enterprises
4.20.1 Autobio
4.20.2 Biobase
4.20.3 Boson Biotechnology
Global Biopharmaceutical Market Scale and YoY Growth, 2000-2009
Global Biopharmaceutical Revenue by Region, 2008
Mergers and Acquisitions of Global Diagnostic Reagent Industry, Jan.2007-Jan.2010 
Sales and Proportion of In-Vitro Diagnostic Reagents of Major European Countries, 2008 
China’s Biopharmaceutical Sales and YoY Growth, 2005-2009
Relevant Polices of Diagnostic Reagent Industry in China
Major Diagnostic Reagent Producers in China
Composition of In-Vitro Diagnostic Reagents in China, 2009
Import Value of Contrast Agent for X-Ray Inspection and Diagnostic Reagent for Patients, Jan.-Aug., 2010
Export Value of Contrast Agent for X-Ray Inspection and Diagnostic Reagent for Patients, Jan.-Aug., 2010
China’s Biochemical Reagent Market Scale and Growth Rate, 2007-2010
China’s Immune Reagent Market Scale and YOY Growth, 2007-2013
Operating Income and Net Profit of KHB, 2006-2010Q1
Operating Income of KHB by Product, 2007-2009
Sales Revenue of Diagnostic Reagent of KHB by Product, 2007-2009
Revenue from Blood Screening Business of KHB,2011 E
Operating Income and Net Profit of Da An Gene, 2006-2010 Q1
Operating Income of Da An Gene by Product, 2007-2009
Operating Income and YOY Growth of Nucleic Acid Diagnostic Reagent of Da An Gene, 2006-2009
Revenue from Blood Screening Business of Da An Gene, 2011
Operating Income and Net Profit of Fosun Pharmaceutical (Group), 2006-2010 H1
Operating Income and Net Profit of Biosino Bio-Technology & Science, 2006-2010 H1
Operating Income of Zhuhai Livzon Diagnostics, 2007-2009
Major Products of Zhuhai Livzon Diagnostics
Operating Income and Gross Profit of ACON, 2007-2008
Operating Income and Gross Profit of Beijing Wantai Biological Pharmacy, 2007-2008
Operating Income and Gross Profit of Shanghai Rongsheng Biotech, 2007-2008
Operating Income and Gross Profit of Beijing Chemclin Biotech, 2007-2008
Detection Reagent of PG Biotech
Operating Income and Net Profit of Kinghawk Pharmaceutical, 2008-2010 H1
Operating Income of Kinghawk Pharmaceutical by Product, 2008-2009
Operating Income and Gross Profit of ABON Biopharm (Hangzhou), 2007-2008
Operating Income and Gross Profit of Shanghai Upper Bio-Tech Pharma, 2007-2008
Operating Income and Gross Profit of Beijing Leadman Biochemical, 2007-2008
Operating Income and Gross Profit of Blue Cross Bio-Medical (Beijing), 2007-2008
Revenue and Gross Profit of Inverness Medical (Shanghai), 2007-2008
Operating Income and Gross Profit of Baso Diagnostics, 2008
Operating Income and Gross Profit of Beijing North Institute of Biological Technology, 2007-2008
Operating Income and Gross Profit of DiaSys Diagnostic Systems (Shanghai), 2007-2008

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号